Novo Nordisk A/S (NVO)
| Market Cap | 227.24B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.93 |
| PE Ratio | 13.00 |
| Forward PE | 12.16 |
| Dividend | $1.18 (2.25%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 17,621,695 |
| Open | 51.44 |
| Previous Close | 50.95 |
| Day's Range | 51.37 - 52.75 |
| 52-Week Range | 45.05 - 139.74 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 112.00 (+113.7%) |
| Earnings Date | Aug 6, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $112.0, which is an increase of 113.70% from the latest price.
News
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
The ongoing compounding/ regulatory headwinds have triggered LLY's and NVO's painful corrections, worsened by the notable market rotation to AI boom. LLY's double beat FQ2'25 performance, raised FY202...
11 Dividend Aristocrats With Excellent Upside Potential In The Next Year
Dividend Growth Outperformance: For over 50 years, dividend growers have delivered market-beating returns with lower volatility. The BTI Example: British American Tobacco went from six years of stagna...
Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH
Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition known as metabolic dysfunction-ass...
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supple...
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
On Thursday, Eli Lilly and Co. LLY said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.
Novo Nordisk Stock Could Benefit From Eli Lilly's Weight-Loss Price Hikes
The pricing of weight-loss drugs like Lilly's Zepbound and Novo's Wegovy is a pressure point for investors.
My Favorite 10 Real-Money Blue-Chip Bargains To Buy In August
Yield, growth, and valuation are the core drivers of long-term returns. Safety and quality protect against catastrophic losses and dividend cuts. Dividend growth stocks have outperformed over 50 years...
It's Time To Be All-In On Novo Nordisk
Novo Nordisk's current valuation is highly attractive, offering a compelling risk-reward for turnaround investors despite recent stock declines and margin pressures. GLP-1 therapies, especially Ozempi...
Novo Nordisk launches weight-loss drug Wegovy in South Africa
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro launched in the coun...
A Cure For Novo Nordisk
NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has administered its own cure - a 70% drop. The bad news should be mostly priced in. $47...
Novo Nordisk: The Falling Knife That Keeps Giving
Novo Nordisk remains a buy despite share price weakness, as strong earnings and robust market share in diabetes and obesity care drive growth. The company's pipeline is rich, with late-stage R&D in ob...
Why is Novo Nordisk excluding Hims & Hers in its lawsuits over Wegovy copies?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. The high-profil...
Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes
I was right with my Strong Sell rating for Novo Nordisk A/S and the main pillar of my bear case: market share erosion in weight loss treatment. FY 2025 guidance cuts—sales 8–14% CER and operating prof...
Novo Nordisk: Enough Is Enough
Novo Nordisk A/S's Q2 earnings disappointed as management issued a cautious growth outlook, but I believe the market overreacted to these headwinds. Despite competition and knock-off products, Novo No...
Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities
I invest for long-term total return, prioritizing dividend growth and quality companies trading at bargain valuations, especially during industry downturns. Despite current headwinds like tariffs and ...
As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers.
Why I Tripled My Novo Nordisk Position
Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below historical averages. Despite lowered 2025 guidance and slower growth, core products...
Novo Nordisk: This Won't Last
Novo Nordisk is still the GLP-1 king, with over 65% market share and blockbuster drugs like Ozempic and Wegovy continuing to drive global growth. The recent stock correction presents a rare long-term ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...
Novo Nordisk extends rebound on Eli Lilly trial results: are investors reversing positions?
Novo Nordisk shares rose over 5% in morning trade on Friday, ranking among the top gainers on the STOXX index, after investors reacted to trial results from Eli Lilly's oral obesity drug candidate, or...
The rise, fall and rise again of Novo Nordisk shares
CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...
Final Trade: AAPL, NOVO, RL
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit – NVO
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Drugmakers racing to launch the first weight-loss pill
Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.